A prospective and randomized placebo-controlled clinical study of 60 patients with RA revealed that andrographolide preparations were effective in relieving RA symptoms, including reductions in rheumatoid factor, IgA and complement C4, with good safety (Burgos et al., 2009). The gene discussed is CD79A; the disease is rheumatoid arthritis.